The company has been working with Steve Finkbeiner's team at Gladstone since January to search for molecules targeting alpha-synuclein, a protein involved in Parkinson's disease.
Topos Bio launches two AI models for hard-to-target proteins
Less than a year after emerging from stealth with an AI model for tracking the ...
firstwordpharma.com